Abstract Number: 1044 • 2019 ACR/ARP Annual Meeting
TGF-β Isoforms Modulate the RNA Cargo of Extracellular Vesicles (Exosomes) Isolated from Cultured Normal Human Lung Microvascular Endothelial Cells: A Mechanistic Link Between Endothelial Cell Dysfunction and the Establishment of a Profibrotic Phenotype in SSc?
Background/Purpose: Extracellular vesicles (EV) are a diverse assortment of lipid bilayer-bound vesicles of various sizes and origin. Exosomes are a subset of EV arising from…Abstract Number: 1049 • 2019 ACR/ARP Annual Meeting
Induction of a Profibrotic Phenotype in Normal Dermal Fibroblasts by Expression of PIM1 Kinase and Demonstration of Antifibrotic Effects of Inhibition of PIM Kinases in Systemic Sclerosis Dermal Fibroblasts
Background/Purpose: There is an urgent unmet need for effective therapeutic approaches for Systemic Sclerosis (SSc), a systemic autoimmune disease characterized by progressive fibrosis of skin…Abstract Number: 1058 • 2019 ACR/ARP Annual Meeting
Inhibition of Histone Readers Bromodomain and Extraterminal Domain Proteins Alleviates Scleroderma Fibrosis
Background/Purpose: Epigenetic regulation, including histone acetylation, plays an important role in scleroderma (SSc) fibrosis. The binding of the bromodomain and extra-terminal domain proteins (BRDs) to…Abstract Number: 1061 • 2019 ACR/ARP Annual Meeting
PI3K-Akt Pathway Plays a Crucial Role in Production of Collagen in Fli1 Deficient Condition and Its Inhibitor Has the Therapeutic Potential in Treating Fibrosis
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease characterized by fibrosis of the skin and internal organs. Previous studies have shown that dermal fibroblast…Abstract Number: 1066 • 2019 ACR/ARP Annual Meeting
Dysregulated IL-6 Dependent Dermal Adenosine Signaling via Adenosine A2A Receptor May Drive Fibrosis in Systemic Sclerosis
Background/Purpose: Altered generation of adenosine from extracellular nucleotides by ectonucleotidases may orchestrate chronic injury responses and promote fibrosis via the adenosine A2A receptor (ADORA2A). We…Abstract Number: 1073 • 2019 ACR/ARP Annual Meeting
Identification of Distinct Pro-Fibrotic Monocyte and Macrophage Subsets in Systemic Sclerosis
Background/Purpose: Chronic inflammation may modulate the balance of classical, intermediate and non-classical monocyte subsets (defined by CD14/CD16 expression)1. Monocytes are heterogeneous and subsets can be…Abstract Number: 1231 • 2019 ACR/ARP Annual Meeting
Improvement in Hepatic Fibrosis Estimated by Fibrosis-4 (FIB-4) Index in Subjects with Chronic Refractory Gout Treated with Pegloticase
Background/Purpose: Hyperuricemia is associated with non-alcoholic fatty liver disease (NAFLD) (Yang C et al. PlosOne2017; 12:e0177249; Jaruvongvanich V et al. Eur J Gastroenterol Hepatol 2017;…Abstract Number: 2429 • 2019 ACR/ARP Annual Meeting
Zipcode-Binding Protein 1 (ZBP1) Facilitates Ro60 Surface Translocation, Cellular Growth and Autoimmune Sequelae
Background/Purpose: Despite the strong association of maternal anti-Ro60 autoantibodies in the development of SS, Neonatal Lupus (NL) and scLE, understanding causality is challenging given that…Abstract Number: 2748 • 2019 ACR/ARP Annual Meeting
Cracking a Novel Profibrotic Molecular Mechanism: lncRNA H19X and DDIT4L Crosstalk
Background/Purpose: Long noncoding RNAs (lncRNAs) are an emerging class of noncoding transcripts involved in the regulation of gene expression in health and disease. LncRNAs function…Abstract Number: 2808 • 2019 ACR/ARP Annual Meeting
Linking Toll-Like Receptor Signaling and Type I Interferons to Inflammation and Fibrosis in a Macrophage/Fibroblast Model of Congenital Heart Block
Background/Purpose: Since one of the strongest associations with antibodies (abs) to SSA/Ro (Ro60) is the development of congenital heart block (CHB), this model provides an…Abstract Number: 374 • 2019 ACR/ARP Annual Meeting
The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases
Background/Purpose: Some patients with autoimmune disease develop progressive fibrosing interstitial lung disease (ILD) characterized by increasing fibrosis on HRCT, decline in lung function, worsening symptoms…Abstract Number: 384 • 2019 ACR/ARP Annual Meeting
Prevalence and Predictors of Fibrosis in Rheumatological Patients on Therapy and Risk Factors for Chronic Liver Disease
Background/Purpose: The assessment of liver stiffness using liver elastography (Fibroscan) has facilitated early diagnosis of hepatic fibrosis in patients with chronic liver disease, but its…Abstract Number: 114 • 2018 ACR/ARHP Annual Meeting
Antifibrotic Regulation By Response Gene to Complement 32 Protein
Background/Purpose: Pulmonary fibrosis is a serious problem in patients with scleroderma lung disease (SLD). Better therapies for pulmonary fibrosis are urgently needed. Identification of new…Abstract Number: 117 • 2018 ACR/ARHP Annual Meeting
Hypomorphic A20 Expression Modulates Fibrosis Susceptibility: Implications for Systemic Sclerosis?
Background/Purpose: Mutiple organ fibrosis, a hallmark of systemic sclerosis (SSc), remains poorly understood. Recent GWAS have uncovered consistent genetic linkage between TNFAIP3, encoding the ubiquitin-editing…Abstract Number: 118 • 2018 ACR/ARHP Annual Meeting
Pharmacological Inhibition of JAK/STAT Signaling By Tofacitinib Prevents Experimental Organ Fibrosis: Novel Therapy for Systemic Sclerosis
Background/Purpose: Synchronous fibrosis in systemic sclerosis (SSc) leads to failure of the skin, lungs and other organs, and has no effective treatments. Myofibroblast activation underlies…
- 1
- 2
- 3
- …
- 8
- Next Page »